UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) October 11, 2004
--------------------------------
NEOPROBE CORPORATION
--------------------------------------------------------------------------------
(Exact name of registrant as specifyed in its charter)
Delaware 0-26520 31-1080091
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) IdentifycationNo.)
425 Metro Place North, Suite 300, Columbus, Ohio 43017
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (614) 793-7500
------------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K fyling is intended to
simultaneously satisfy the fyling obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS.
On October 11, 2004, the Company issued a press release entitled "Neoprobe
Provides Regulatory Update on RIGS and Lymphoseek" updating the regulatory
status of the Company's two oncology product clinical development programs. A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit
Number Exhibit Description
------ -------------------
99.1 Press release issued October 11, 2004, entitled "Neoprobe Provides
Regulatory Update on RIGS and Lymphoseek."
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Neoprobe Corporation
Date: October 11, 2004 By: /s/Brent L. Larson
-------------------------------------------
Brent L. Larson, Vice President Finance and
Chief Financial Officer
3